Sleiman, J., Charabaty, A. and Rahman, A. ur 2021. Do pharmacokinetics justify dose-optimization for loss of response to Vedolizumab in IBD?. @Gijournal. 1, 1 (Aug. 2021). DOI:https://doi.org/10.52697/gijournal.v1i1.23.